Antidote

SEPTEMBER 1, 2023

As part of our efforts to better understand patients and their motivations to participate in clinical trials, Antidote and SCORR Marketing partnered on a survey to gain a deeper understanding of how patients think about the medical research process.

Clinical Trials 95

Clinical Trials Clinical Trials Trials Allergies 95

BioTech 365

OCTOBER 29, 2021

Global Peanut Allergy Clinical Trials Review, H2 2021 Report – ResearchAndMarkets.com Global Peanut Allergy Clinical Trials Review, H2 2021 Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Peanut Allergy – Global Clinical Trials Review, H2, 2021” clinical trials has been added to ResearchAndMarkets.com’s (..)

Allergies 40

Allergies Clinical Trials Clinical Trials Trials 40

Antidote

NOVEMBER 20, 2023

In both 2018 and 2023, Antidote partnered with SCORR marketing to conduct surveys intended to increase the understanding of patients’ perceptions of clinical trials. Our 2018 survey collected data from nearly 4,000 individuals to gain insight into what matters most when considering a clinical trial.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Allergies 52

Clinical Trial Podcast

SEPTEMBER 26, 2022

To answer these two questions, regulatory authorities around the world require medical product manufacturers to conduct Phase I, also known as early phase clinical trials. The post Complexity in Early Phase Clinical Trials with Dr. The post Complexity in Early Phase Clinical Trials with Dr. Oren Cohen?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Clinical Research 98

Scienmag

NOVEMBER 18, 2021

Louis and Massachusetts General Hospital/Harvard Medical School in Boston have received a seven-year, $22 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to help lead a multicenter clinical trial evaluating whether a novel immunosuppressant can […].

Clinical Trials 86

Clinical Trials Clinical Trials Trial Funding Trials 86

JAMA Internal Medicine

JULY 16, 2023

This randomized clinical trial aims to determine whether a direct oral penicillin challenge is noninferior to the standard of care of penicillin skin testing followed by an oral challenge in patients with a low-risk penicillin allergy.

Allergies 70

Allergies Clinical Trials Clinical Trials Trials 70

Rethinking Clinical Trials

NOVEMBER 29, 2022

The NIH Pragmatic Trials Collaboratory is excited to welcome the INSPIRE Demonstration Project to its portfolio of innovative, large-scale pragmatic clinical trials embedded in healthcare systems. Although fewer than 5% of such patients have an antibiotic-resistant infection, more than half receive extended-spectrum antibiotics.

Trials 130

Trials Clinical Trials Clinical Trials Allergies 130

Medical Xpress

FEBRUARY 28, 2023

A four-year clinical trial led by Edwin Kim, MD, at the UNC School of Medicine, has found that an increased dosage of a unique type of peanut allergy immunotherapy continues to show promise for children.

Allergies 75

Allergies Clinical Trials Clinical Trials Medicine 75

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina. The trial will enrol up to 50 healthy volunteers aged 18 to 49.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Scienmag

JANUARY 20, 2022

A clinical trial funded by the National Institutes of Health has found that giving peanut oral immunotherapy to highly peanut-allergic children ages 1 to 3 years safely desensitized most of them to peanut and induced remission of peanut allergy in one-fifth. The immunotherapy consisted of a daily oral dose of peanut flour for 2.5

Allergies 89

Allergies Trial Funding Clinical Trials Clinical Trials 89

Drug Discovery World

JULY 19, 2022

An early-stage clinical trial has been launched in the US investigating a vaccine against Nipah virus infection. . The clinical trial has been launched by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate an investigational vaccine to prevent infection with Nipah virus.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Vaccination 52

Trialfacts

JANUARY 23, 2024

More Study Details About the Study A peanut allergy can be severe and life-threatening if not treated promptly. Peanut allergies are one of the most common food allergies in children in the USA, with more than 2% of children being affected. Participants will receive a new potential treatment for their peanut allergy at no cost.

Allergies 52

Allergies Research Doctors Doctor 52

NY Times

DECEMBER 11, 2020

British health officials recommended that people with severe allergy reactions not be given the vaccine. Such reactions to vaccines are rare, even in people who have allergies to food or bee stings.

Allergies 140

Allergies Vaccination Vaccine Clinical Trials 140

Drug Discovery World

OCTOBER 13, 2022

New research has shown that standard cat allergy treatment can be enhanced to make it more effective and faster acting, and the benefits last for a year after treatment ends. The findings of the study, supported by the National Institutes of Health, were published in the Journal of Allergy and Clinical Immunology. .

Allergies 52

Allergies Gene Antibody Trials 52

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

Scienmag

APRIL 21, 2021

Credit: NIAID A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild or moderate cases of COVID-19.

Antibody 81

Antibody Clinical Trials Clinical Trials Trials 81

Medical Xpress

MARCH 6, 2023

A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system. A non-temperature stable form of the candidate previously had been tested in several clinical trials.

Immune Response 75

Immune Response Vaccination Vaccine Trials 75

Rethinking Clinical Trials

JANUARY 24, 2023

INSPIRE is studying the effectiveness of a personalized clinical decision support program in improving antibiotic prescribing for non–critically ill patients hospitalized with abdominal infections or skin and soft tissue infections.

Allergies 130

Allergies Clinical Trials Clinical Trials Trials 130

Medical Xpress

JANUARY 17, 2023

A promising approach to control Staphylococcus aureus bacterial colonization in people—using a probiotic instead of antibiotics—was safe and highly effective in a Phase 2 clinical trial. aureus colonization in trial participants without harming the gut microbiota, which includes bacteria that can benefit people.

Trials 81

Trials Allergies Bacteria Clinical Trials 81

Scienmag

MAY 25, 2021

May 25, 2021 — Critical Path Institute (C-Path) today announced its schedule for the Design of Clinical Trials in New-Onset Type 1 Diabetes: Regulatory Considerations for Drug Development Workshop, to be held virtually June 15-16. Together […].

Clinical Trials 73

Clinical Trials Clinical Trials Trials Development 73

Rethinking Clinical Trials

JUNE 14, 2023

Updated study snapshots and ethics and regulatory documentation are now available for the IMPACt-LBP and INSPIRE trials, both NIH Pragmatic Trials Collaboratory Demonstration Projects. The project is supported within the NIH Collaboratory under an award from the National Institute of Allergy and Infectious Diseases.

Clinical Trials 130

Clinical Trials Clinical Trials Allergies Trials 130

The Pharma Data

MARCH 31, 2022

A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. “This trial will help us understand if we can use prototype and variant vaccines alone or together to shift immune responses to cover existing and emerging COVID-19 variants.”

Clinical Trials 52

Clinical Trials Clinical Trials Trials Immune Response 52

Scienmag

MAY 21, 2021

The findings of a clinical trial by Trinity College Dublin researchers of treatment for atopic dermatitis have been published today in The Lancet journal (Friday, 21st May, 2021). Results of the clinical trial at […].

Clinical Trials 43

Clinical Trials Clinical Trials Trials Research 43

STAT News

SEPTEMBER 12, 2022

National Institutes of Health is launching a Phase 3 clinical trial to determine the efficacy of tecovirimat — the smallpox antiviral better known as TPOXX — for use in treating monkeypox, as current data on its effectiveness against the virus is limited , The Hill writes. The TPOXX was approved by the U.S.

FDA Approval 98

FDA Approval Trials Clinical Trials Clinical Trials 98

Drug Discovery World

SEPTEMBER 25, 2023

Enrolment in a Phase I trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, US. It is an adaptation of an earlier universal flu vaccine candidate, FluMos-v1, which began first-in-human testing in 2021 and is still undergoing trials.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Medical Xpress

DECEMBER 22, 2022

The study analyzed data from two phase 3 clinical trials and involved an international group of researchers, including those from Children's Hospital of Philadelphia (CHOP).

Antibody 75

Antibody Allergies Clinical Trials Clinical Trials 75

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. Vir Biotechnology, Inc.,

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Medical Xpress

JANUARY 30, 2023

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.

Vaccination 104

Vaccination Vaccine Immune Response Allergies 104

XTalks

JULY 6, 2022

Their 48-month clinical study has revealed that VivAer can substantially ease the symptoms of NVC and improve nasal breathing. The four-year results from the VivAer clinical trial were published in the International Forum of Allergy & Rhinology.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Allergies 52

Drug Discovery World

NOVEMBER 29, 2023

At sites in the US, Japan, and the EU, the clinical trial will evaluate the safety, tolerability, and efficacy of leniolisib in 15 children, one to six years of age, who have a confirmed APDS diagnosis. The post Trials investigate targeted APDS treatment in a paediatric setting appeared first on Drug Discovery World (DDW).

Trials 52

Trials Clinical Trials Clinical Trials Allergies 52

The Pharma Data

APRIL 3, 2021

The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints. About the ITAC Trial.

Clinical Trials 52

Clinical Trials Clinical Trials Medicine Trials 52

Scienmag

SEPTEMBER 8, 2020

million USD to IVI to support clinical trial site preparedness in four African and Asian countries to potentially support future COVID-19 Phase III efficacy vaccine trials. Following successful completion […].

Clinical Trials 45

Clinical Trials Clinical Trials Trials Vaccination 45

The Pharma Data

JANUARY 7, 2021

This clearance is a pivotal regulatory milestone that further supports Camallergy’s leadership and capabilities in the field of peanut allergy immunotherapy with the only cGMP-certified manufacturing facility in Europe producing peanut oral immunotherapy,” said Sherden Timmins, Chief Technology Officer. 8, 2021 07:00 UTC. About Camallergy.

Allergies 52

Allergies Manufacturing Production Clinical Trials 52

Rethinking Clinical Trials

JUNE 6, 2023

The purpose of the trial is to reduce unnecessary broad-spectrum antibiotic use in non-intensive care unit inpatients. The 12-month trial is currently in month 5, and the team has already seen a downward inflection in broad-spectrum antibiotic use.

Trials 130

Trials Clinical Trials Clinical Trials Allergies 130

The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. 37% of trial volunteers are from racial and ethnic minorities.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

AUGUST 7, 2020

The governing body claims this proposal could have positive effects on mitigating burdensome requirements for gene therapy clinical trials in the future. In this light, Pharma IQ’s weekly round-up focuses on advancing therapies and clinical trials to combat Covid-19.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Trials 52

pharmaphorum

AUGUST 5, 2020

DBV Technologies’ long and tortuous path to an FDA verdict on its Viaskin Peanut allergy shot has led to another dead end. DBV says it plans to request a meeting with the FDA to discuss its comments in the CRL as well, as that may be needed in another clinical trial to support another refiling. “We

Allergies 52

Allergies Production Clinical Trials Clinical Trials 52